CALCA and migraine disorder: Methods: Re‐MATE (Real‐Migraine Antibodies Treatments Evidence) is an observational, retrospective study comparing the following variables at 3 and 6 months after initiating an anti‐CGRP treatment: number of monthly migraine days, number of days using rescue medication, retention rate at 6 months, and side effects.